Clarapath Inc. is a medical technology company at the forefront of transforming pathology laboratory operations through intelligent automation and AI-powered solutions. Their flagship product, SectionStar™, is an AI-driven, fully automated system for tissue sectioning, orientation, and placement onto slides, addressing critical bottlenecks and variability in traditional histopathology. By integrating robotics, machine vision, and artificial intelligence, Clarapath aims to improve diagnostic accuracy, increase laboratory efficiency, reduce turnaround times, and alleviate the strain caused by a shortage of skilled histotechnologists. Their solutions are designed to enhance the quality and consistency of tissue samples, ultimately supporting pathologists in delivering timely and precise diagnoses for improved patient care.
The Hawthorne headquarters serves as the primary hub for research and development, engineering, manufacturing of their robotic systems (like SectionStar™), corporate strategy, and administrative operations.
The facility likely includes advanced R&D laboratories, cleanroom environments for medical device assembly, engineering workshops, and collaborative workspaces designed to foster innovation in robotics and AI.
Clarapath's work culture is expected to be highly innovative, collaborative, and mission-driven, focusing on precision, quality, and solving complex challenges in the medical field. There's likely an emphasis on continuous learning and technological advancement.
The headquarters is central to Clarapath's pioneering work in automated pathology, serving as the birthplace and development center for its core technologies. Its location provides strategic advantages for partnerships and talent acquisition.
While primarily based in the United States with its headquarters in New York, Clarapath is focused on serving the global pathology market. Their current efforts are concentrated on North America, with strategic intentions to expand into Europe and other key international regions. Global functions are supported through direct sales and support teams, and potentially through partnerships and distributors in various countries to make their automated pathology solutions accessible worldwide.
120 Bradhurst Ave, Suite 2500
Hawthorne
NY
USA
Address: N/A
To provide localized support, expand market reach, and facilitate customer relationships in regions beyond the immediate vicinity of their Hawthorne headquarters. This allows for responsive service and market penetration.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Clarapath' leadership includes:
Clarapath has been backed by several prominent investors over the years, including:
No major, publicly announced executive new hires or exits have been prominently featured for Clarapath Inc. in the last 12-18 months. The core leadership team appears to be stable based on available information. Any changes may have been internal promotions or not widely publicized.
Discover the tools Clarapath uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Clarapath likely utilizes standard corporate email formatting conventions. The most common formats include [first_initial][last]@clarapath.com or [first].[last]@clarapath.com. For example, an employee named Jane Doe might have an email address like jdoe@clarapath.com.
[first_initial][last]@clarapath.com
Format
efeinstein@clarapath.com
Example
85%
Success rate
Clarapath Website (Press Release) • March 4, 2024
Clarapath announced it will showcase PathInsight™, its new AI-powered data insights software, at the United States and Canadian Academy of Pathology (USCAP) 2024 Annual Meeting. PathInsight is designed to provide lab managers with actionable insights into their operations....more
MedTech Breakthrough Awards • May 11, 2023
Clarapath's SectionStar™, the first AI-powered, all-in-one tissue sectioning and transfer system, was recognized as the 'Best New Diagnostic Technology Solution' in the 7th annual MedTech Breakthrough Awards....more
Clarapath Website (Press Release) • March 21, 2023
Clarapath announced the completion of a $26 million Series C financing round. The funding will be used to accelerate the commercialization of its SectionStar system and expand its operational capabilities....more
Business Wire • October 20, 2022
Clarapath received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its SectionStar™ system. This designation is intended to expedite the development and review of innovative medical devices....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Clarapath, are just a search away.